Syngene Delivers Steady Growth in Q4 FY25; Full-Year PAT Down 8%
ECONOMY & POLICY

Syngene Delivers Steady Growth in Q4 FY25; Full-Year PAT Down 8%

Syngene International reported a strong performance in Q4 FY25 with revenue from operations rising 11% year-on-year to Rs 10.18 billion, crossing the Rs 10 billion mark for the first time. The quarter also saw sequential revenue growth of 8%, supported by robust performance across research, development, and manufacturing services. Operating EBITDA grew 9% YoY, with a margin of 35%, while profit after tax stood at Rs 1.83 billion. 

For the full fiscal year, revenue from operations rose 4% to Rs 36.42 billion. However, profit after tax before exceptional items declined 8% to Rs 4.75 billion, impacted by sectoral headwinds in the first half. Adjusted for one-offs, full-year PAT remained flat with 1% YoY growth. EBITDA margin for the year moderated to 29%. 

Key highlights included the acquisition of a biologics manufacturing site in Baltimore, USA, enhancing Syngene’s single-use bioreactor capacity to 50KL and expanding its footprint in the US biologics CDMO market. The company also launched SYNe-MAP™, a proprietary B2B e-commerce platform to streamline biological assay services. 

Looking ahead, Syngene expects FY26 revenue growth in the early teens on an underlying basis, with reported growth likely in the mid-single digits due to client-level inventory balancing. EBITDA margins are expected to moderate to the mid-twenties due to costs from the new US facility. The Board has recommended a final dividend of Rs 1.25 per share for FY25. 

(BSE)     

Syngene International reported a strong performance in Q4 FY25 with revenue from operations rising 11% year-on-year to Rs 10.18 billion, crossing the Rs 10 billion mark for the first time. The quarter also saw sequential revenue growth of 8%, supported by robust performance across research, development, and manufacturing services. Operating EBITDA grew 9% YoY, with a margin of 35%, while profit after tax stood at Rs 1.83 billion. For the full fiscal year, revenue from operations rose 4% to Rs 36.42 billion. However, profit after tax before exceptional items declined 8% to Rs 4.75 billion, impacted by sectoral headwinds in the first half. Adjusted for one-offs, full-year PAT remained flat with 1% YoY growth. EBITDA margin for the year moderated to 29%. Key highlights included the acquisition of a biologics manufacturing site in Baltimore, USA, enhancing Syngene’s single-use bioreactor capacity to 50KL and expanding its footprint in the US biologics CDMO market. The company also launched SYNe-MAP™, a proprietary B2B e-commerce platform to streamline biological assay services. Looking ahead, Syngene expects FY26 revenue growth in the early teens on an underlying basis, with reported growth likely in the mid-single digits due to client-level inventory balancing. EBITDA margins are expected to moderate to the mid-twenties due to costs from the new US facility. The Board has recommended a final dividend of Rs 1.25 per share for FY25. (BSE)     

Next Story
Infrastructure Transport

Mumbai-Ahmedabad Bullet Train Set to Launch by 2028

India’s first bullet train is set to revolutionize high-speed travel along the western corridor, with the Mumbai-Ahmedabad high-speed rail project aiming for a 2028 launch. This announcement marks a major milestone in India’s infrastructure goals, as it promises to reduce travel time between the two economic hubs from eight hours to just three.Spanning a planned 508-kilometre stretch, the corridor stands as a flagship example of Indo-Japanese collaboration in technology and engineering. Once operational, the train is expected to transform intercity mobility and place India among the select..

Next Story
Infrastructure Transport

Mumbai-Gandhinagar Train Service Enhances Passenger Capacity

The Mumbai Central–Gandhinagar Capital Vande Bharat Express has increased its passenger capacity by adding four additional AC chair car coaches to meet the growing commuter demand on one of India’s busiest business corridors. This upgrade, effective from 11 May, raised the train’s seating capacity from 1,128 to 1,440 passengers, allowing it to serve 936 more passengers daily in both directions. The increase was described as a practical measure to accommodate the surging demand on the busy Mumbai–Ahmedabad–Gandhinagar route, which regularly operates at over 150 percent seat occupancy...

Next Story
Infrastructure Urban

Delhi Plans 12 Sewage Plants to Clean Najafgarh Drain Efficiently

Delhi’s ambitious plan to improve the water quality of the Yamuna River has gained significant momentum as the Delhi Jal Board (DJB) has begun work on 12 new sewage treatment plants (STPs) aimed at reducing the volume of untreated sewage being discharged from the Najafgarh Drain.This initiative forms part of the ongoing efforts to clean the Yamuna and restore the river’s health, which has long been a critical environmental issue for the national capital. Given the alarming pollution levels in the Yamuna, experts and officials consider this project a vital step toward addressing the persist..

Advertisement

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Advertisement

Talk to us?